Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
Matinas BioPharma (MTNB) announced a strategic collaboration with National Resilience, Inc., focusing on the oral delivery of nucleic acids using Matinas' lipid nanocrystal (LNC) platform. This agreement includes a comprehensive research program for designing, formulating, and testing nucleic acid formats. The LNC technology may enhance intracellular drug delivery, offering advantages over traditional methods with no observed immunogenicity or cytotoxicity. CEO Jerome D. Jabbour expressed excitement about the collaboration, emphasizing its distinct nature from ongoing projects with BioNTech.
Matinas BioPharma Holdings, Inc. (MTNB) announced significant progress in its Phase 2 EnACT study for MAT2203, achieving a remarkable 95% two-week survival rate in cryptococcal meningitis patients. The treatment surpassed primary endpoint thresholds, showing a 90% overall survival rate through 18 weeks. The pivotal Phase 3 trial is set to commence in Q1 2023, backed by the NIH. Financially, the company reported $33.1 million in cash, sufficient for operations through 2023, with a reduced net loss of $5.5 million for Q3 2022.
Matinas BioPharma Holdings (MTNB) announced a conference call on November 2, 2022, at 4:30 PM ET to discuss third-quarter financial results for the period ending September 31, 2022. The company specializes in intracellular delivery technologies for nucleic acids and small molecules via its lipid nanocrystal (LNC) platform. Their innovative approach aims to enhance drug delivery efficiency, positioning Matinas for future collaborations and product developments.
Matinas BioPharma Holdings announced positive interim results for MAT2203, an oral formulation of amphotericin B, from its Phase 2 EnACT trial for cryptococcal meningitis treatment. Notably, the two-week survival rate in Cohort 4 reached 95% among 40 patients, exceeding the primary endpoint for CSF yeast clearance. MAT2203 demonstrated favorable safety, showing no kidney toxicity over six weeks of treatment. A pivotal Phase 3 trial is set to begin in Q1 2023, aimed at further validating MAT2203's efficacy.
Matinas BioPharma (MTNB), a clinical-stage biopharmaceutical company, announced that CEO Jerome D. Jabbour will present at the ThinkEquity Investment Conference on October 26, 2022, at 10:30 a.m. ET. This event will take place at the Mandarin Oriental Hotel in New York City, where investor meetings are also scheduled. The company focuses on enhancing the intracellular delivery of nucleic acids and small molecules using its lipid nanocrystal (LNC) platform technology, aimed at addressing challenges in the drug delivery process.
Matinas BioPharma Holdings (MTNB) announced that its abstract, Oral Encochleated Amphotericin B for Cryptococcal Meningitis: A Phase II Randomized Trial (EnACT), was selected as the IDSA Awardee at IDWeek 2022. The presentation will be led by Dr. Mucunguzi Atukunda on October 21, 2022, in Washington, DC. The recognition underscores the potential impact of MAT2203, an oral formulation of amphotericin B, in treating cryptococcal meningitis. CEO Jerome D. Jabbour highlighted the enthusiasm surrounding MAT2203's future as it prepares for a Phase 3 trial in early 2023.
Matinas BioPharma (MTNB) recently announced significant findings from the EnACT Trial of MAT2203 for treating cryptococcal meningitis and pulmonary mucormycosis. The oral formulation shows 5 to 10-fold greater efficacy than conventional therapies like liposomal amphotericin B. Presentations will occur at IDWeek 2022 in Washington DC, showcasing MAT2203's safety and potential in Phase 3 studies. The goal is to establish multiple orphan indications for this innovative antifungal therapy.
Matinas BioPharma Holdings announces the appointment of Eric J. Ende as Chairman of the Board, effective October 1, 2022. Ende succeeds Herbert J. Conrad, who will remain on the board as an independent director. The leadership change reflects the company's progress and aims to enhance its strategic direction. Ende, who joined the board in 2017, brings extensive experience from previous roles, including at Genzyme and Merrill Lynch. Matinas BioPharma focuses on its lipid nanocrystal technology for drug delivery, with ongoing clinical trials for products like MAT2203 and MAT2501.
Matinas BioPharma (MTNB) announced that its CEO, Jerome D. Jabbour, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 1:30 p.m. ET in New York City. The company is focused on enhancing intracellular delivery using its lipid nanocrystal platform technology. They have two clinical-stage assets: MAT2203, an oral antifungal, and MAT2501, an oral treatment for bacterial infections. Investors can access a webcast of the presentation on their website following the event.
Matinas BioPharma Holdings (MTNB) reported significant progress with MAT2203, its lead candidate for cryptococcal meningitis, enrolling 75% of patients in Cohort 4 of the EnACT study. Topline data is expected by early Q4 2022. The FDA has clarified a streamlined Phase 3 trial design, with an anticipated start in Q1 2023. The company has $38.5 million in cash, adequate to support operations through 2023. Management expects ongoing collaboration with BioNTech on mRNA applications. However, a potential partnership for LYPDISO is halted. The net loss for Q2 2022 was $5.9 million.